subscribeSubscribe
Astellas touts 2-year trial results for GA drug Izervay

Astellas touts 2-year trial results for GA drug Izervay
Eric Sagonowsky FIERCE PHARMA
06 Nov 2023
Share Share
Apellis counters Izervay results with long-term data of its own

Apellis counters Izervay results with long-term data of its own
Fraiser Kansteiner FIERCE PHARMA
06 Nov 2023
Share Share
IZERVAY Monthly or Every Month Reduced Geographic Atrophy Lesion Growth

IZERVAY Monthly or Every Month Reduced Geographic Atrophy Lesion Growth
PR NEWSWIRE
04 Nov 2023
Share Share
Astellas touts 2-year trial of Izervay, but questions remain

Astellas touts 2-year trial of Izervay, but questions remain
Kevin Dunleavy FIERCE PHARMA
19 Sep 2023
Share Share
Iveric Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY

Iveric Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY
PR NEWSWIRE
18 Sep 2023
Share Share
EMA Accepts Iveric`s Marketing Authorization Application for Avacincaptad Pegol

EMA Accepts Iveric`s Marketing Authorization Application for Avacincaptad Pegol
PR NEWSWIRE
17 Aug 2023
Share Share
Iveric Receives FDA Approval for IZERVAY, a New Treatment for Geographic Atrophy

Iveric Receives FDA Approval for IZERVAY, a New Treatment for Geographic Atrophy
PR NEWSWIRE
05 Aug 2023
Share Share
CARVYKTI Receives Approval from Japan’s Ministry of Health

CARVYKTI Receives Approval from Japan’s Ministry of Health
BUSINESSWIRE
27 Sep 2022
Share Share
Iveric Bio reports positive PhIII readout as shares surge, FDA filing planned

Iveric Bio reports positive PhIII readout as shares surge, FDA filing planned
Paul Schloesser ENDPTS
07 Sep 2022
Share Share
Iveric Bio Announces Positive Data from Zimura GATHER2 PIII Trial

Iveric Bio Announces Positive Data from Zimura GATHER2 PIII Trial
PRESS RELEASE
06 Sep 2022
Share Share